Objective： Recent evidence suggests that Oct-4 is highly expressed in several cancers, and its expression contributes to tumor growth. In this study, we investigated the level of Oct-4 expression in rectal adenocarci...Objective： Recent evidence suggests that Oct-4 is highly expressed in several cancers, and its expression contributes to tumor growth. In this study, we investigated the level of Oct-4 expression in rectal adenocarcinoma, and evaluated the prognostic significance of Oct-4 expression in these cases. Methods： The immunohistochemical expression of Oct-4 was evaluated in 52 formalin-fixed paraffin-embedded postoperative rectal adenocarcinoma tissue samples. The impact of the immunoreactivity of Oct-4 in regard to clinical outcome was determined by Kaplan-Meier and log-rank. Results： The expression level of Oct-4 ranged from 0 to 18.5%. There was no significant association between Oct-4 expression and gender （P=0.772）, age （P=0.123）, clinical stage （P=0.391）, and histological grade （P=0.056）. The 3-year local recurrence-free rates with negative and positive expression of Oct-4 were 83.5% and 75.0%, respectively （P=0.583）. The 3-year metastasis-free rates with negative and positive expression of Oct-4 were 88.6% and 61.9%, respectively （P=0.035）. The 3-year overall survival rates with negative and positive expression of Oct-4 were 77.9% and 49.0%, respectively （P=0.037）. Conclusion： The results suggest that embryonic stem cell marker Oct-4 expression may have prognostic significance in patients with rectal adenocarcinoma. However, to confirm this more and larger studies are required.展开更多
基金supported by the grant from Jiangsu Natural Science Program(No.BK2009126).
文摘Objective： Recent evidence suggests that Oct-4 is highly expressed in several cancers, and its expression contributes to tumor growth. In this study, we investigated the level of Oct-4 expression in rectal adenocarcinoma, and evaluated the prognostic significance of Oct-4 expression in these cases. Methods： The immunohistochemical expression of Oct-4 was evaluated in 52 formalin-fixed paraffin-embedded postoperative rectal adenocarcinoma tissue samples. The impact of the immunoreactivity of Oct-4 in regard to clinical outcome was determined by Kaplan-Meier and log-rank. Results： The expression level of Oct-4 ranged from 0 to 18.5%. There was no significant association between Oct-4 expression and gender （P=0.772）, age （P=0.123）, clinical stage （P=0.391）, and histological grade （P=0.056）. The 3-year local recurrence-free rates with negative and positive expression of Oct-4 were 83.5% and 75.0%, respectively （P=0.583）. The 3-year metastasis-free rates with negative and positive expression of Oct-4 were 88.6% and 61.9%, respectively （P=0.035）. The 3-year overall survival rates with negative and positive expression of Oct-4 were 77.9% and 49.0%, respectively （P=0.037）. Conclusion： The results suggest that embryonic stem cell marker Oct-4 expression may have prognostic significance in patients with rectal adenocarcinoma. However, to confirm this more and larger studies are required.
